International Medical Cannabis Conference University of Bern (IMCCB-25) - Programme

www.imccb.org

Wednesday 12 February

17.00-18.00 Pre-Registration on Site

19.00 Meet-the-Speakers Dinner (invitation only)



Information about location and directions

Thursday 13 February

8.00 Registration / Welcome Coffee

9.00-9.15 Opening and Welcome Addresses

Jürg Gertsch & Rudolf Brenneisen, Conference Chairs

Representative of Rectorate University of Bern

Petra Baeriswy, Swiss Federal Office of Public Health

9.15-10.45 Session 1 Endocannabinoid System and Pharmacology (Chair Jürg Gertsch)

L-1 The Day Anandamide Almost Died and Other Endocannabinoid Stories

Daniele Piomelli, University of California Irvine, USA

L-2 Endocannabinoidome Signaling: From Gut to Brain and Across Different Kingdoms, and Intersections with Plant Cannabinoids

Vincenzo di Marzo, Université Laval, Quebec, Canada & Institute of Biomolecular Chemistry, C.N.R. Italy

L-3 Cannabinoid and Stress – Mechanistic Aspects

Beat Lutz, University of Mainz, Germany

10.45-11.45 Coffee Break, Poster Viewing, Visit the Exhibition, Networking

11.45-13.00 Session 2 From Cannabis to Effects and Medicines (Chair Matthias Hamburger)

L-4 50 Years of Phytochemistry and Analytics

Mahmoud ElSohly, University of Mississippi, Oxford, USA

L-5 Personalized Cannabis Medicines – What is the Evidence?

Guillermo Moreno-Sanz, Khiron Europe, Spain

L-6 Sites and Mechanisms Underlying Cannabinoid-Induced Antinociception

David Finn, University of Galway, Ireland

13.00-13.30 Panel 1

L-1 to L-6 Ask the experts - panel discussion (Chairs Jürg Gertsch & Matthias Hamburger)

13.30-14.30 Lunch Break, Poster Viewing, Visit the Exhibition, Networking

14.30-15.30 Session 3 Cannabis-based Medicines (CBMs) in a Clinical Setting (Chair Reto Agosti)

L-7 CBMs in Pain Disorders – What is the Evidence?

Matthias Karst, Hannover Medical School, Germany

L-8 Cannabinoids for Neurodegeneration - Fact or Fiction?

Markus Weber, Cantonal Hospital St. Gallen, Switzerland

L-9 CBMs in Psychiatric and Substance Use Disorders

Patrik Roser, University Hospital of Psychiatry Zürich, Switzerland

15.30-16.30 Session 4 Cannabinoids Between Research and Therapeutic Applications (Chair Rudolf Brenneisen)

L-10 Cannabinoid-based Therapies for Treating Metabolic Diseases Yossi Tam, The Hebrew University of Jerusalem, Israel

L-11 The Value of Real-World Evidence in Cannabis Therapies

Anne Katrin Schlag, Drug Science & Imperial College London, UK

L-12 The Use of Tetrahydrocannabinol in Palliative Cancer Patients

Thomas Herdegen, University Clinics of Kiel, Germany

16.30-17.00 Panel 2

L-7 to L-12 Ask the experts - panel discussion (Chairs Reto Agosti & Rudolf Brenneisen)

17.00-18.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking

18.00-19.00 Session 5 Towards Evidence-Based Cannabis Medicines, Opportunities and Risks I (Chair Claude Vaney)

L-13 CBMs in Sleep Disorders

Kirsten Müller-Vahl, Medizinische Hochschule Hannover, Germany

L-14 Medical Cannabis for Behavioral Symptoms in Patients with Severe Dementia: The MedCanDem Study

Federica Bianchi, Geneva University Hospital, Switzerland

L-15 Cannabis in Pain Treatment : The Challenge between Science and Clinical Evidence

Thomas R. Tölle, Technische Universität München, Germany

19.00-19.30 Panel 3

L-13 to L-15 Ask the experts - panel discussion (Chair Claude Vaney)

19.30 APÉRO RICHE

Friday 14 February

8.30 Registration / Welcome Coffee

9.00-10.00 Session 6 Towards Evidence-Based Cannabis Medicines, Opportunities and Risks II (Chair Simon Nicolussi)

L-16 Cannabinoid Drug-Drug Interactions

Kent E. Vrana, Pennsylvania State University College of Medicine, Hershey, USA

L-17 Risks of Cannabis-based Medicine

Margaret Haney, Columbia University Medical Center, New York, USA

L-18 Challenges and Opportunities of Cannabis e-Cigarettes (e-Joints)

Reto Auer, University of Bern, Switzerland

10.00-10.30 Panel 4

L-16 to L-18 Ask the experts - panel discussion (Chair Simon Nicolussi)

10.30-11.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking

11.00-12.30 Session 7 Short Presentations of Various Topics (Chair Federica Bianchi)

L-19 SOP I: MEMORY & Research within the Florida Medical Marijuana Consortium

Almut Winterstein, University of Florida, Gainesville, USA

L-20 SOP II: tba

L-21 SOP III: tba

L-22 SOP IV: tba

L-23 SOP V: tba

12.30-13.00 Panel 5

L-19 to L-23 Ask the experts - panel discussion (Chairs Federica Bianchi)

13.00-14.00 Lunch Break, Poster Viewing, Visit the Exhibition, Networking

14.00-16.00 Session 8 Monitoring Real-World CBM Applications and Country Reports (Chair Aleksandra Kupferberg)

L-24 PEP: Leveraging Real-World Evidence for Advancing Cannabis-Based Medicinal Product Therapies

Garvin Hirt, Copeia GmbH, Bergisch Gladbach, Germany

L-25 Reporting System MeCanna – Features, Challenges and Opportunities

Christian Werz, Federal Office of Public Health, Switzerland

L-26 Country Report: USA

Amie Goodin, University of Florida, Gainesville, USA

L-27 Country Report: Germany

Konrad F. Cimander, Wedemark, Germany

L-28 Country Report V: Spain

Guillermo Moreno-Sanz, Khiron Europe, Spain

L-29 Country Report: Latin America

Sandra Carillo, University of Panama, Panama

16.00-16.30 Panel 6

L-24 to L-29 Ask the experts - panel discussion (Chair Aleksandra Kupferberg)

16.30-17.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking

17.00-18.00 Session 9 The Journey from Non-Medical to Evidence-Based Medical Cannabis (Chair Thomas Herdegen)

L-30 What is Clinical Evidence?

John Ioannidis, Stanford University, USA

L-31 Non-medical Cannabis Use: First Results from a Swiss Pilot Trial (Cann-L)

Frank Zobel, Addiction Switzerland, Lausanne, Switzerland

L-32 Hot Topics in Cannabis Research

Jürg Gertsch, University of Bern, Switzerland

18.00-18.30 Panel 7

L-24 to L-29 Ask the experts - panel discussion (Chairs Thomas Herdegen, tba)

18.30 Awards & Closing Remarks

Jürg Gertsch & Rudolf Brenneisen